Vanguard Group Inc Immunity Bio, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,539,590 shares of IBRX stock, worth $85.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,539,590
Previous 13,328,525
1.58%
Holding current value
$85.6 Million
Previous $66.9 Million
8.67%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding IBRX
# of Institutions
191Shares Held
66.7MCall Options Held
2.27MPut Options Held
3.23M-
State Street Corp Boston, MA14.2MShares$89.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$65.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.48MShares$22 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.55MShares$9.79 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY1.44MShares$9.07 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $2.53B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...